BIO Applauds House Committee Vote to Repeal IPAB

Washington, DC (March 6, 2012) – The Biotechnology Industry Organization (BIO) applauded the House Energy and Commerce Committee’s passage of the Medicare Decisions Accountability Act, H.R. 452, which would repeal the Independent Payment Advisory Board (IPAB) established in the health care reform law.

“Repealing IPAB is essential to protecting Americans’ access to quality medical care and is particularly important to populations such as seniors who rely on Medicare,” stated BIO President and CEO Jim Greenwood.  “We urge Congress to pass the Medicare Decisions Accountability Act in order to safeguard patient access to life-saving therapies.”